Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026

Denali Therapeutics (Nasdaq: DNLI) will report its second quarter 2026 financial results and business highlights for the period ended June 30, 2026, on Thursday, August 6, 2026.

Rhea-AI Summary

Denali Therapeutics (Nasdaq: DNLI) will report its second quarter 2026 financial results and business highlights for the period ended June 30, 2026, on Thursday, August 6, 2026. Management will host a conference call and webcast at 4:30 p.m. ET (1:30 p.m. PT) to discuss the results and provide a business update.

The live webcast and slide presentation will be available via the Investors section of Denali’s website, with a replay archived for a limited time. Denali describes itself as a biotechnology company developing biotherapeutics that cross the blood-brain barrier using its TransportVehicle™ platform.

Argus Jul 28 session 5 alerts

+2.04% close to close 0.7x rel. volume Open Argus

Details

News Market Reaction – DNLI

+3.4% Peak Tracked

-3.9% Trough Tracked

$3.89B Market Cap

In the Jul 28 session, DNLI gained 2.04%, reflecting a moderate positive market reaction. Argus tracked a peak move of +3.4% during that session. Argus tracked a trough of -3.9% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The prior earnings event was followed by a -0.46% 24-hour move, while DNLI's recent news record incl...

Analysis

The prior earnings event was followed by a -0.46% 24-hour move, while DNLI's recent news record included four negative reactions among five events. The scheduled update leaves results and business metrics unreported; watch the disclosed figures and outlook.

Key Figures

Fiscal period: Second quarter 2026 Quarter end: June 30, 2026 Report date: August 6, 2026 +2 more

Fiscal period

Second quarter 2026

Financial results and business highlights

Quarter end

June 30, 2026

Reporting period

Report date

August 6, 2026

Scheduled financial results announcement

Conference call time

4:30 p.m. Eastern Time

August 6, 2026

Pacific call time

1:30 p.m. Pacific Time

August 6, 2026

Historical Context

5 past events · Latest: Jul 09

5 events

1. Jul 09

   AAIC presentation

   24h Move

   -5.6%

   Opening plenary address and platform updates at AAIC 2026

2. Jun 18

   Voucher sale

   24h Move

   -0.8%

   Agreement to sell Rare Pediatric Disease Priority Review Voucher for $195 million

3. May 21

   Phase 2b study

   24h Move

   -3.4%

   BIIB122 failed primary and secondary endpoints in early-stage Parkinson's disease

4. May 07

   Q1 earnings report

   24h Move

   -0.5%

   Q1 results included a $128.4 million net loss and approximately $1.05 billion cash

5. Mar 25

   FDA approval

   24h Move

   +7.2%

   FDA granted accelerated approval for AVLAYAH in pediatric Hunter syndrome

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

blood-brain barrier, FDA-approved, lysosomal storage disorders

3 terms

blood-brain barrier medical

"designed to cross the blood-brain barrier (BBB) using its proprietary"

A protective barrier of tightly packed cells and supporting tissue that controls what substances in the blood can enter the brain, acting like a security checkpoint that keeps out most pathogens and many drugs while allowing essential nutrients through. For investors, the barrier matters because whether a therapy can cross or safely bypass it often determines clinical success, regulatory approval and commercial potential for treatments of brain disorders.

FDA-approved regulatory

"the first FDA-approved biologic specifically designed to cross the BBB"

FDA-approved means a medical product, drug, device or treatment has passed the U.S. Food and Drug Administration’s review for safety and effectiveness for a specific use. Think of it like a formal safety and performance seal that allows the product to be marketed for that purpose in the U.S.; for investors, approval reduces regulatory uncertainty, enables sales and reimbursement pathways, and can materially affect a company’s revenue prospects and valuation.

lysosomal storage disorders medical

"neurodegenerative diseases, lysosomal storage disorders and other serious diseases"

A group of inherited conditions where cells cannot break down and clear certain molecules, like a clogged recycling center inside cells causing harmful buildup that damages organs and the nervous system. Investors care because these disorders create clear targets for specialized treatments, often qualify for orphan-drug incentives and accelerated review, and can drive focused clinical programs and high-value niche markets if therapies prove safe and effective.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that it will report financial results and business highlights for the second quarter ended June 30, 2026, on Thursday, August 6, 2026.

Following the announcement, Denali's management will host a conference call and webcast on Thursday, August 6, 2026, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss Denali’s second quarter 2026 financial results and provide a general business update.

The live webcast, along with an accompanying slide presentation, may be accessed through the Investors section of Denali's website at www.denalitherapeutics.com or by clicking here. A replay of the webcast will be archived on Denali’s website for a limited time following the call.

About Denali Therapeutics

Denali Therapeutics Inc. is a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier (BBB) using its proprietary TransportVehicle™ platform. With the first FDA-approved biologic specifically designed to cross the BBB, a clinically validated delivery platform and a growing portfolio of therapeutic candidates across all stages of development, Denali is advancing toward its goal of delivering effective medicines to transform life for people with neurodegenerative diseases, lysosomal storage disorders and other serious diseases. For more information, please visit www.denalitherapeutics.com.

Investor Contact:

Laura Hansen

hansen@dnli.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Denali Therapeutics (DNLI) report its Q2 2026 financial results?

Denali Therapeutics plans to report its Q2 2026 financial results on Thursday, August 6, 2026. According to Denali Therapeutics, the report will cover the quarter ended June 30, 2026, and will be accompanied by a management conference call and webcast.

What time is Denali Therapeutics (DNLI) Q2 2026 earnings conference call on August 6, 2026?

The Denali Therapeutics Q2 2026 earnings call is scheduled for 4:30 p.m. Eastern Time on August 6, 2026. According to Denali Therapeutics, this corresponds to 1:30 p.m. Pacific Time and will include financial results and a general business update.

How can investors access the Denali Therapeutics (DNLI) Q2 2026 earnings webcast?

Investors can access the Denali Therapeutics Q2 2026 earnings webcast through the Investors section of the company’s website. According to Denali Therapeutics, the live webcast will include slides, and a replay will be archived online for a limited period.

Will there be a replay of the Denali Therapeutics (DNLI) Q2 2026 earnings call?

Yes, a replay of the Denali Therapeutics Q2 2026 earnings webcast will be available on the company’s website. According to Denali Therapeutics, the archived replay will remain accessible in the Investors section for a limited time following the call.

What does Denali Therapeutics (DNLI) focus on in its biotechnology pipeline?

Denali Therapeutics focuses on biotherapeutics designed to cross the blood-brain barrier using its TransportVehicle platform. According to Denali Therapeutics, it has an FDA-approved biologic using this approach and a pipeline targeting neurodegenerative diseases, lysosomal storage disorders, and other serious conditions.

What will Denali Therapeutics discuss during the Q2 2026 DNLI earnings call?

Denali Therapeutics will discuss second quarter 2026 financial results and provide a general business update. According to Denali Therapeutics, management will review performance for the quarter ended June 30, 2026, and highlight key business developments during the webcast.